MEGAN TERRELL: Open Payments
NPI 1124724679 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,845 in 98 payments from 21 companies in 2025. Trend: 2023 $1,870 · 2024 $2,272 · 2025 $1,845
Food & beverage: $1,845
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 11 | $231 |
| ABBVIE INC. | 12 | $199 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 9 | $147 |
| Ardelyx, Inc. | 7 | $135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $133 |
| GENZYME CORPORATION | 6 | $133 |
| QOL Medical, LLC | 5 | $116 |
| Aimmune Therapeutics, Inc. | 7 | $112 |
| Ipsen Biopharmaceuticals, Inc | 5 | $101 |
| Gilead Sciences, Inc. | 4 | $95 |
Products named: REZDIFFRA, DUPIXENT, IBSRELA, ENTYVIO, Sucraid, ZENPEP, IQIRVO, RELISTOR.
Industry payments across AL — which companies pay providers there.
